ILCA Guidelines on Management of ICC


Timothy Pawlik, MD (USA)

Given the increasing incidence of intrahepatic cholangiocarcinoma (iCCA), as well as the growing recognition of iCCA as a distinct cancer, and the large number of recent publications on this disease, the International Liver Cancer Association (ILCA) governing board noted it was both timely and topical to develop practice guidelines on iCCA. These guidelines are largely based on a consensus of a multidisciplinary, geographically diverse writing committee using a data-supported approach, and subsequently reviewed by a separate Practice Guidelines committee of ILCA. These recommendations suggest preferred approaches to the diagnostic and therapeutic aspects of care, and are intended to be flexible, in contrast to standards of care, which should be supported by robust evidence-based data. Thus, the guidelines have two principle goals: (1) to provide physicians with pragmatic clinical recommendations; and (2) to identify areas of interest for future research, including suggestions for conducting clinical trials. The evidence and recommendations in these guidelines have been graded according to the Grading of Recommendations Assessment Development and Evaluation (GRADE) system. The GRADE system classifies the evidence as high, moderate, low or very low quality. The strength of recommendation is either strong or weak based on the quality of underlying evidence, outcomes and cost. The presentation will present the practice guidelines for the diagnosis and management of iCCA based on this work.